ライフサイエンスコーパス: duration of therapy

1 ne or both drugs for >or=80% of the expected duration of therapy).

2 th regards to antifungal agent employed, and duration of therapy.

3 etectable in the majority of animals for the duration of therapy.

4 istered for 1 month, 2 months, or the entire duration of therapy.

5 ve immune responses that otherwise limit the duration of therapy.

6 leave questions unanswered regarding optimal duration of therapy.

7 aintained an undetectable viral load for the duration of therapy.

8 , various estrogen preparations or doses, or duration of therapy.

9 ct of CPAP is evident only after an extended duration of therapy.

10 ism is sensitive using a sufficient dose and duration of therapy.

11 sist and become the dominant variant for the duration of therapy.

12 ir inherent immunogenicity, which limits the duration of therapy.

13 operative site bleeding was not affected by duration of therapy.

14 ients in the aIGB group to complete the full duration of therapy.

15 there is no consensus regarding the optimal duration of therapy.

16 r the use of oral antibiotic therapy and the duration of therapy.

17 and now treats boys and girls with the same duration of therapy.

18 intervals of 3-5 days, with a 14-day median duration of therapy.

19 erms of dosage, route of administration, and duration of therapy.

20 elated with the number of injections and the duration of therapy.

21 CV RNA at week 4 and qualified for the short duration of therapy.

22 efit tuberculosis patients by shortening the duration of therapy.

23 ce of cure and the opportunity for a shorter duration of therapy.

24 ic hypothermia is dependent on the onset and duration of therapy.

25 Infection risk is also likely to vary with duration of therapy.

26 ffectively prevented acute rejection for the duration of therapy.

27 of level 1 evidence to guide the choice and duration of therapy.

28 c or vasopressor support and correlated with duration of therapy.

29 failure of this treatment increases with the duration of therapy.

30 cure rates might be achievable with shorter durations of therapy.

31 response rates and the potential for shorter durations of therapy.

32 144/231 [62%]; p=0.0095), and a shorter mean duration of therapy (12.5 days [SD 10.7] vs 17.7 [28.1];

33 After the switch to tocilizumab (median duration of therapy, 18 months), the median annualized r

34 Ongoing uncertainties include the duration of therapy, acceptable risks, and intensity of

35 Median duration of therapy among Medicare patients was shorter

36 ribavirin doses for >or=80% of the expected duration of therapy and (2) patients who received reduce

37 e of episodes of acute intoxication and that duration of therapy and cumulative dose are the major de

38 Explicit instructions about expected duration of therapy and discussions about medication adv

39 nterferon + ribavirin because of the shorter duration of therapy and high rates of SVR (89%-90%).

40 e with morphine is associated with a lengthy duration of therapy and hospitalization.

41 SU after eOIT is enhanced with longer duration of therapy and increases the likelihood of tole

42 -positive solid tumors with response-adapted duration of therapy and local control.

43 s suggest a higher response rate with longer duration of therapy and non-type 1 genotypes.

44 romising, many unanswered questions, such as duration of therapy and optimal end points to evaluate e

45 research is needed to determine the optimal duration of therapy and potential for biologics to modif

46 type is an important criteria in determining duration of therapy and predictor of sustained virologic

47 ysis revealed associations between prolonged duration of therapy and rare variants, notably within th

48 Secondary outcomes included the duration of therapy and rates of subsequent infections.

49 There was no significant association between duration of therapy and resistance for any antibiotic cl

50 ave helped guide decisions earlier regarding duration of therapy and resuscitation status.

51 The short duration of therapy and small volume irradiated allowed

52 The optimal duration of therapy and the balance of risks and benefit

53 Evaluation of effects based on duration of therapy and time off IFN prior to transplant

54 ting drugs are being assessed to shorten the duration of therapy and to treat multidrug-resistant tub

55 The median durations of therapy and follow-up were 29 and 36 months

56 features (i.e., cumulative HCQ dose and the duration of therapy) and quantitative imaging biomarkers

57 atty acids as a treatment, (b) determine the duration of therapy, and (c) test whether there is benef

58 We evaluated the incidence, duration of therapy, and appropriateness of antibiotic p

59 raphics, ocular history, type of drops used, duration of therapy, and duration of follow-up as well a

60 advantages of induction dosing, the optimal duration of therapy, and further understanding of the fr

61 Approaches to empiric treatment selection, duration of therapy, and other management considerations

62 Approaches to empiric treatment, duration of therapy, and other management considerations

63 ic treatment, transitioning to oral therapy, duration of therapy, and other management considerations

64 ic treatment, transitioning to oral therapy, duration of therapy, and other management considerations

65 calcium supplementation, type of vitamin D, duration of therapy, and sex, but reduced sample sizes m

66 There is a need to evaluate antibiotic use, duration of therapy, and stewardship in low- and middle-

67 atifloxacin) regimens have failed to shorten duration of therapy, and the new tuberculosis drug pipel

68 ine demographics, PHT medication(s), dosage, duration of therapy, and time to referral.

69 B, factors associated with treatment of ASB, durations of therapy, and frequency of complications inc

70 was given in lieu of or after DI, with total duration of therapy approximately 3 years for boys and 2

71 paration, dose, route of administration, and duration of therapy are dictated by the stage of disease

72 h patient-focused outcomes exploring shorter duration of therapy are feasible (NCT06892860).

73 and trials that evaluate optimal timing and duration of therapy are in progress as part of induction

74 serum vancomycin concentrations and greater duration of therapy are independently associated with in

75 variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing rando

76 s and antagonists in heart failure vary with duration of therapy, as do the effects of beta-AR agonis

77 e that combination of IFN and ribavirin with duration of therapy based on the viral genotype, is a co

78 ddressing corticosteroid molecule, dose, and duration of therapy, based on currently available eviden

79 n alfa plus cytarabine (65.6%) and the short duration of therapy before crossover in these patients (

80 Duration of therapy before study enrollment was correlat

81 C), but questions remain surrounding optimal duration of therapy, benefits and risks of ICI rechallen

82 ore, race, overall antibiotic utilization or duration of therapy between the 2 yrs of study.

83 The duration of therapy beyond which continued use is futile

84 It occurred more commonly with greater duration of therapy, but improved following dose reducti

85 for extracorporeal treatment is provided and duration of therapy can be guided through the careful mo

86 Drug dose, patient age, and duration of therapy did not account for the variability.

87 Duration of therapy did not significantly differ between

88 Longer durations of therapy did not appear to increase the risk

89 atherogenesis and have implications for the duration of therapies directed at leukocyte recruitment.

90 to estimates of the effect on mortality and duration of therapy effectiveness.

91 s; method and equipment used for evacuation; duration of therapy; evidence of complications; results

92 benefit of novel agent-based CT versus fixed duration of therapy (FDT) in patients with newly diagnos

93 ne the relationship between HBIg failure and duration of therapy, five additional treatment failures

94 Questions remain about optimal duration of therapy following deployment of drug-eluting

95 the initiation of anti-TNFalpha therapy, the duration of therapy following the onset of inactive dise

96 ons are needed; efforts to assess and reduce duration of therapy for CAP should be strongly considere

97 The duration of therapy for CAP was excessive at our institu

98 The appropriate duration of therapy for catheter-associated Staphylococc

99 nd ongoing work to elucidate the appropriate duration of therapy for children and adolescents with PE

100 nd ongoing work to elucidate the appropriate duration of therapy for children with provoked thrombosi

101 The optimal duration of therapy for chronic osteomyelitis remains un

102 assess the optimal therapeutic approach and duration of therapy for cryptococcosis in transplant rec

103 Cumulative dose of dexamethasone and duration of therapy for dexamethasone and prednisolone o

104 Type, dose, and duration of therapy for each patient were at the physici

105 Early detection and adequate duration of therapy for ESBL-producing Enterobacteriacea

106 LDL-C-lowering therapy; 2) the intensity and duration of therapy for inducing atherosclerosis regress

107 a 3-month course seemed to be an appropriate duration of therapy for most patients.

108 Optimal duration of therapy for patients with HCV genotype 6 is

109 8 h in the electronic medical record and the duration of therapy for pneumonia and culture-negative s

110 atasvir-containing regimens could reduce the duration of therapy for these patients.

111 The duration of therapy for this syndrome remains unclear bu

112 high rates of treatment of ASB and prolonged durations of therapy for ASB and symptomatic UTIs.

113 t of asymptomatic bacteriuria (ASB) and long durations of therapy for symptomatic urinary tract infec

114 By shortening the duration of therapy from the currently recommended 12 we

115 A standard of care and optimal duration of therapy have not been established for patien

116 the effects of novel therapeutic agents and duration of therapy, have become available.

117 for significant confounders (age, ethnicity, duration of therapy, hepatitis C virus status, and HOMA-

118 a levels correlated best with the cumulative duration of therapy hours (p = 0.03), rather than hourly

119 itment for early rapid diagnosis, shortening duration of therapy, improving treatment outcomes, and p

120 latent infection and possibly shortening the duration of therapy in active TB.

121 Several trials to reduce the duration of therapy in MDR and drug-susceptible tubercul

122 harms and benefits of longer versus shorter duration of therapy in older adults.

123 ddressed the issues of choice of therapy and duration of therapy in selected bacteremic disease, such

124 ly explored as biomarkers to personalize the duration of therapy in TB.

125 ribavirin can be used to define the optimal duration of therapy in the setting of HEV infection.

126 sine [5-FC] for a median of 2 weeks); median duration of therapy including azole eradication therapy

127 Additionally, specific drug delivery issues, duration of therapy, initiation of treatment and managem

128 or which optimisation of dose, frequency, or duration of therapy is desirable.

129 owever, quantifying the real-world impact of duration of therapy is hindered by bias common in observ

130 Evaluating the optimal duration of therapy, long-term safety of novel pharmacot

131 e of disease, specific drug delivery issues, duration of therapy, management of bony metastases with

132 mposition of the probiotic cocktail, dosage, duration of therapy, mechanisms of the antimicrobial act

133 d on culture results, and using the shortest duration of therapy needed for documented infections.

134 Long duration of therapy needed for HIV-infected children req

135 d pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis an

136 s the potential to substantially shorten the duration of therapy needed to cure human tuberculosis.

137 ard of care, but the optimal combination and duration of therapy needs to be determined.

138 ed infection, possibly related to inadequate duration of therapy, occurred among 32% who ultimately a

139 comycin (odds ratio = 1.112; p < 0.001), and duration of therapy (odds ratio = 1.041; p </= 0.001) we

140 We enrolled 34,701 patients with mean duration of therapy of 18 months.

141 significant, consistent effect on the median duration of therapy of laBCC and mBCC.

142 ted effect estimates for antibiotic type and duration of therapy on the richness of obligate anaerobe

143 effects, depending on the cell type and the duration of therapy, one of which includes the ability t

144 justing for drug exposure and accounting for duration of therapy, only neutropenia was independently

145 proved by suppressing acid and extending the duration of therapy (optimization).

146 R, 1.79; 95% CI, 1.15-2.78), and appropriate duration of therapy (OR, 2.13; 95% CI, 1.24-3.64).

147 tics could have the potential to shorten the duration of therapy, prevent resistance development and

148 t after clinical response and an appropriate duration of therapy, probably at least 12 months, appear

149 30.4 weeks, which indicates that the 48-week duration of therapy provided a suboptimal probability of

150 The duration of therapy ranged from 2 to 72 hours.

151 The duration of therapy ranged from 23 to 188 hrs in group 1

152 oxic, but existing studies focus on extended durations of therapy rather than the brief empiric cours

153 as well as the appropriate starting dose and duration of therapy remain controversial.

154 proved response rates, although the adequate duration of therapy remains unclear.

155 es are necessary to assess the efficacy, the duration of therapy required for effective results, and

156 The duration of therapy required to completely eliminate the

157 ith satisfaction with life in both cases and duration of therapy required to receive hospital dischar

158 ents as possible as well as scaling back the duration of therapy required.

159 Longer duration of therapy showed statistically significant inc

160 e., HCQ daily dose, HCQ cumulative dose, and duration of therapy) showed significant differences betw

161 : -0.30; 95% CI: -4.19, 3.59; p = 0.878) and duration of therapy (slope: 0.18; 95% CI: -0.22, 0.59; p

162 udy offers the first estimate of the average duration of therapy that is required to eliminate stem-l

163 In determining duration of therapy, the Expert Panel recommends a share

164 se, including the particular azole used, the duration of therapy, the reason therapy was discontinued

165 The mean duration of therapy was 10.8 days for liposomal amphoter

166 The median duration of therapy was 12 weeks (range, 2 to 111).

167 The mean duration of therapy was 12.9 mo (range, 3 to 24 mo).

168 sus 800 mg (758.2-800.0) placebo, and median duration of therapy was 120.0 days (IQR 43.0-266.0) for

169 Median duration of therapy was 16 months (range: 5 to 35 months

170 The median duration of therapy was 2.79, 0.4, and 1.63 years, respe

171 The median duration of therapy was 20 days (range, 8-77 days); 26 p

172 Median duration of therapy was 24.9 months [95% confidence inte

173 The mean duration of therapy was 27 months.

174 Median duration of therapy was 35.8 weeks (95% CI, 35.1-36.5 we

175 The total duration of therapy was 42 weeks followed by 6 months of

176 The median duration of therapy was 57 months (interquartile range,

177 Mean (SD) duration of therapy was 6.0 (3.3) months (range, 1-18.4

178 As a 2 x 2 factorial design, duration of therapy was also addressed and was previousl

179 The duration of therapy was approximately 9 months, and no m

180 The median anticipated duration of therapy was comparable at 28 (interquartile

181 Duration of therapy was defined as the time period betwe

182 The duration of therapy was determined by baseline patient c

183 c status of chromosomes 1p and 11q; ultimate duration of therapy was determined by overall response.

184 Total duration of therapy was determined by treating clinician

185 The duration of therapy was meant to be limited to four cycl

186 Furthermore, duration of therapy was not associated with the risk of

187 However, the duration of therapy was short, and whether therapy of lo

188 T-cell count, antiretroviral drug class and duration of therapy, was 73.5 (95% CI 25.7-210.5; P < .0

189 The mean dose of losartan and the mean duration of therapy were 14.2+/-5.3 mg. kg(-1). d(-1) an

190 he effects of vitamin D because the dose and duration of therapy were insufficient to raise 25(OH)D c

191 The mortality and duration of therapy were similar for patients treated wi

192 mptoms prior to therapy, treatment type, and duration of therapy) were recorded.

193 the estimated parameters was correlated with duration of therapy when actual CPAP use was not taken i

194 ntibodies will achieve greater intensity and duration of therapy, while allowing repeat administratio

195 The duration of therapy with AmB (14 vs 11 days, p=0.05) and

196 Little is known about the optimal duration of therapy with an anti-tumor necrosis factor (

197 dence intervals for categories of cumulative duration of therapy with any of the three agents combine

198 ntroversy persists regarding the appropriate duration of therapy with benzathine penicillin G in pers

199 ing antibiotics to PCT levels may reduce the duration of therapy without increasing treatment failure

200 ctivity of current regimens would reduce the duration of therapy without sacrificing efficacy, thereb